Drug-Resistant Tuberculosis in Children and Adolescents in the Republic of Sakha (Yakutia)
International Journal of Biomedicine. 2018;8(1):51-55.
Originally published March 15, 2018
The aim of the study was to determine the prevalence of drug-resistant tuberculosis among children and adolescents in the Republic of Sakha (Yakutia) (RS(Y)) and the features of its clinical manifestation, in order to improve the prevention and treatment of the disease.
We monitored a total of 250 children and adolescents with tuberculosis (TB) who underwent inpatient treatment in the Yakut NPZ in 2012-2016: The patients included 34(13.6%) children in the 0-2 age group, 80(32%) in the 3-6 age group, 74(29.6%) in the 7-14 age group, and 62(24.8%) adolescents between 15 and 17 years. The timing of the development of the disease from the time of primary infection with Mycobacterium tuberculosis differed significantly depending on the age of children. In young children, compared with older children, signs of the disease appeared at an earlier time. In the structure of clinical forms of TB, the differences were observed depending on the age of the children:
- In children under 2 years, the lesion of intrathoracic lymph node tuberculosis (ITLN) was most common, as well as generalized TB
- For children aged between 3 and 6 years, the lesion of ITLN was characteristic
- For older children, the different clinical forms of TB were characteristic.
The expression of immunological tests depended on the age of the patients and the number of ITLN lesions. Drug resistance to anti-tuberculosis drugs was found in 21 (36.8%) patients; multidrug-resistant TB was mainly registered in adolescents and multidrug resistance was mainly primary. Drug resistance to isoniazid, rifampicin, and streptomycin was the most frequent.
Thus, it has been established that the outcome of the disease and the timing of the onset of clinical involution of the disease depend on many factors, including the timeliness of disease detection, the age of the patient, the dissemination of TB process, and others.
- WHO. Tuberculosis. Fact sheet. Updated October 2017. Available from:
- WHO. Childhood TB. Available from: http://www.who.int/tb/areas-of-work/children/en/
- WHO. What is multidrug-resistant tuberculosis (MDR-TB) and how do we control it? Online Q&A. Reviewed January 2018. Available from: http://www.who.int/features/qa/79/en/
- Vinokurova MK, Alexandrov VL, Yakovleva LP, Oshchepkova NM. Trends in the development of the epidemiological situation of tuberculosis in the Republic Sakha (Yakutia) in 2004-2011. YAKUT MEDICAL JOURNAL. 2013;(1):58-63. [Article in Russian].
- Borisov SE, Sokolova GB. Etiotropic treatment of tuberculosis with drug-resistant M. Tuberculosis: Views and Recommendations of International Organizations. Consilium medicum. 2001;3(12):595-600. [Article in Russian].
- Ivanova L.A. Characteristics of drug resistance of M. Tuberculosis in patients with destructive pulmonary tuberculosis in modern conditions. New technologies in the diagnosis and treatment of tuberculosis of various organs and systems. St. Petersburg; 1998: 2:58. [in Russian].
- Mishin V.Yu. Controlled chemotherapy for respiratory tuberculosis in modern conditions. The problem of drug resistance. Russian Medical Journal. 2000;8(12): 496-501. [Article in Russian].
- Sokolova G.B. New approaches to the treatment of drug-resistant forms of tuberculosis. Chemotherapy of tuberculosis. 2000;(9):30-37. [Article in Russian].
- Chukanov V.I. Basic principles for treatment of patients with pulmonary tuberculosis. Russian Medical Journal. 1998;17:1138-42. [Article in Russian].
- Zhukova M.P. Prevalence of drug-resistant M. Tuberculosis among tuberculosis patients with bacteria discharge. Problemi Tuberkuloza. 1998; (1):14-16. [Article in Russian].
- Luginova EF, Ivanova AP, Zolotareva NA, Mokhnachevskaya AI. Efficiency of preventive measures in children and adolescents from foci of drug-resistant tuberculosis. Collection of Scientific Works of the National Congress on Diseases of the Respiratory System. М., 2002:294.
Received December 24, 2017.
Accepted January 6, 2018.
©2018 International Medical Research and Development Corporation.